JP Morgan Chase
VYGR icon

JP Morgan Chase’s Voyager Therapeutics VYGR Stock Holding History

JP Morgan Chase’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-59,300
Closed -$748K – 5817
2020
Q2 		$748K Buy
+59,300
New +$690K ﹤0.01% 3668

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase's VYGR Position: Q2 2026 in Review

JP Morgan Chase reduced its Voyager Therapeutics (VYGR) stake by 0.24% in Q2 2026, selling an estimated $2.49K and leaving 276,211 shares worth $989K. The position accounts for ﹤0.01% of the portfolio, ranked #4679.

JP Morgan Chase first reported a position in VYGR in Q4 2015 and has held it in 42 quarters since. The position peaked at $8.59M in Q2 2019. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • JP Morgan Chase held 276,211 shares of Voyager Therapeutics worth $989K as of Q2 2026.
  • JP Morgan Chase sold 656 Voyager Therapeutics shares in Q2 2026, an estimated $2.49K.
  • Voyager Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4679 holding.
  • JP Morgan Chase first reported a position in Voyager Therapeutics in Q4 2015 and has held it in 42 quarters since.
  • JP Morgan Chase's Voyager Therapeutics position peaked at $8.59M in Q2 2019.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.